Interim Results From Biodesix, Inc. Study Indicate That Veristrat Testing Impacts Treatment Decisions Across All Stages Of Non-Small Cell Lung Cancer
Published: Sep 15, 2017
BOULDER, Colo., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Interim analysis of a new study examining the impact of VeriStrat testing on treatment decisions in patients with non-small cell lung cancer (NSCLC) is being presented today at the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Poster Title: “INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC”
Poster Presentation: 8:45AM-10:15AM CDT
Session: Pathology; Posters
Presenter: Paul Walker, MD
“Historic data have shown the utility of VeriStrat in patients with advanced stage NSCLC. Results of this interim analysis of the INSIGHT study show that VeriStrat testing also impacts treatment planning for patients with early stage disease,” said Dr. Paul Walker, lead study author. “Treatment strategies were significantly different for patients in this cohort with a VeriStrat-Good status versus those who tested VeriStrat-Poor.”
INSIGHT is a national, multi-institutional prospective observational trial of patients with NSCLC for whom physicians ordered VeriStrat testing. The primary endpoint of the study is observing the impact of VeriStrat on treatment planning. An interim analysis of 714 patients enrolled between May 2016 and June 2017 was conducted on the primary study endpoint. The analysis focused on the 170-patient subset with stage IA-IIIA disease at the time of study entry.
The interim analysis showed that patients who tested VeriStrat – Good (VS-Good) were treated significantly differently than patients who tested VeriStrat – Poor (VS-Poor), receiving non-systemic treatments such as radiation therapy (11%) or surgery (12%), or observation (11%). Patients who tested VS-Poor did not receive these treatments. Nearly all patients with a VS-Poor test result received systemic therapies (97%), compared to 66% of the VS-Good patients. In contrast, per multivariate analysis, treatment decisions were not impacted by other prognostic factors (performance status, histology, and age).
About the VeriStrat Test
The VeriStrat test is a predictive and prognostic blood-based proteomic test that helps guide treatment decisions for patients with advanced non-small-cell lung cancer. The test is used to assess disease aggressiveness by characterizing host response to the tumor, classifying patients as either VeriStrat-Good or VeriStrat-Poor.
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic liquid biopsy tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests and with the Biodesix Lung Reflex™ testing strategy, for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of personalized medicine, Biodesix is developing new tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
VeriStrat, GeneStrat and Biodesix are registered trademarks of Biodesix, Inc. All other trademarks referenced herein are the property of their respective owners.
For more information about Biodesix, please visit www.Biodesix.com.
Biodesix Contact: Rachel Biederman